LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company,
announced that results from the ExteNET Phase III clinical trial of
neratinib in patients with early stage HER2 positive breast cancer were
published in the journal The Lancet Oncology. The article
entitled “Neratinib after trastuzumab-based adjuvant therapy in patients
with HER2-positive breast cancer (ExteNET); a multicentre, randomized,
double-blind, placebo-controlled, phasemore...